Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of interventions linked to treatable traits in acute critical illness in adults to enable precision medicine: Data enabled Bayesian adaptive platform randomised clinical trial with embedded biological characterisation (TRAITS Trial)

Trial Profile

Evaluation of interventions linked to treatable traits in acute critical illness in adults to enable precision medicine: Data enabled Bayesian adaptive platform randomised clinical trial with embedded biological characterisation (TRAITS Trial)

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 30 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Baricitinib (Primary) ; Budesonide (Primary) ; Imatinib (Primary)
  • Indications Critical illness; Inflammation; Lymphopenia; Respiratory insufficiency; Shock
  • Focus Therapeutic Use
  • Acronyms TRAITS

Most Recent Events

  • 08 Nov 2023 Status changed from not yet recruiting to recruiting.
  • 08 Nov 2023 Planned initiation date changed from 1 Nov 2023 to 27 Nov 2023.
  • 08 Nov 2023 Status changed to not yet recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top